Genelux logo
Genelux
GNLX | NASDAQ
Chart Builder DCF Calculator
$1.92
+$0.05 (+2.95%)
At close: Nov 16, 2026, 4:00 PM ET
$1.80
-$0.12 (-6.16%)
After-hours: Nov 16, 2026, 7:20 PM ET

Genelux Company Profile

Company profile explained

Company Profile

Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.

Key Executives

Name Position
Thomas Zindrick Chairman, Chief Executive Officer & President
Matthew Pulisic Chief Financial Officer and Principal Financial & Accounting Officer
Eric Groen General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development
Jason Litten Chief Medical Officer
Joseph Cappello Chief Technical Officer
Ralph Smalling Vice President & Head of Regulatory Affairs
Yong Yu Chief Scientific Officer

Latest SEC Filings

Date Type Title
Sep 02, 2026 4 Filing
Sep 02, 2026 4 Filing
Sep 02, 2026 4 Filing
Aug 13, 2026 10-Q Quarterly Report
Aug 04, 2026 4 Filing
Aug 04, 2026 4 Filing
Aug 04, 2026 4 Filing
Jul 02, 2026 4 Filing
Jun 22, 2026 8-K Current Report
Jun 18, 2026 4 Filing
View All SEC Filings ➞
Genelux
Genelux logo
Country United States
IPO Date Jan 26, 2023
Industry Biotechnology
Sector Healthcare
Employees 26
CEO Thomas D. Zindrick

Contact Details

2625 Townsgate Road Westlake Village, California 91361 United States

Stock Details

Ticker Symbol GNLX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001231457
CUSIP Number 36870H103
ISIN Number US36870H1032
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.